Company ReNeuron Group Plc London S.E.
Equities
Biotechnology & Medical Research
Business Summary
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell-based Therapies
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +31.51% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, United States, China and South East Asia
74.3
%
| 0 | 70.5 % | 0 | 74.3 % | +38.73% |
United States
25.7
%
| 0 | 29.5 % | 0 | 25.7 % | +14.29% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Suzanne Hancock
COO | Chief Operating Officer | - | 01/17/01 |
Chief Tech/Sci/R&D Officer | - | 03/22/03 | |
Shaun Stapleton
LAW | General Counsel | - | 01/15/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Walton
BRD | Director/Board Member | 61 | 22/22/22 |
Iain Ross
CHM | Chairman | 71 | 01/21/01 |
Director/Board Member | 61 | 14/21/14 | |
Michael Owen
BRD | Director/Board Member | 73 | 04/15/04 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 57,173,760 | 38,116,952 ( 66.67 %) | 0 | 66.67 % |
Company contact information
![address ReNeuron Group Plc](https://cdn.zonebourse.com/static/address/4005458.png)
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.44B | |
+41.02% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |